Latest News:

Sep 19, 2019

PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial

Read More

Sep 03, 2019

PDS Biotechnology to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Read More

Aug 01, 2019

PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update

Read More

PDS BIOTECHNOLOGY HAS MERGED WITH EDGE THERAPEUTICS

 

ABOUT PDS BIOTECHNOLOGY

PDS Biotechnology is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

All of PDS’s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.